A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Completed
Ariad Pharmaceuticals
Phase 1/Phase 2
2011-09-20
The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to
determine the safety profile of orally administered brigatinib, including: the maximum
tolerated dose (MTD), dose limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and
pharmacokinetic (PK) profile. Then, once the RP2D is established, an expansion phase will
assess the preliminary anti-tumor activity of brigatinib, both in non-small cell lung cancer
(NSCLC) with ALK gene rearrangement (including participants with active brain metastases) or
mutated EGFR, and in other cancers with abnormal targets against which brigatinib is active.
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Completed
Ariad Pharmaceuticals
Phase 2
2014-06-04
The purpose of this study is to evaluate the efficacy and safety of two different dosing
regimens of brigatinib (AP26113) in participants with ALK-positive locally advanced or
metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with
crizotinib.
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Recruiting
Academic Thoracic Oncology Medical Investigators Consortium
Phase 2
2017-03-09
The purpose of this study is to evaluate the safety and effectiveness of this investigational
drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small
cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got
worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act
on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
